Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells

Biochemical Pharmacology

Volumn 55, Issue 9, 1998, Pages 1465-1473

  Etore, Florence ^a   Tenu, Jean Pierre ^a   Teiger, Emmanuel ^b   Adnot, Serge ^b   Lonchampt, Marie Odile ^c   Pirotzki, Eduardo ^c   Le Doan, Trung ^a  

^a CNRS   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c Institut Henri Beaufour   (France)

Author keywords

Compartmentalization; Digitonin; Oligodeoxynucleotides; Permeabilization; Smooth muscle cells; Uptake

Indexed keywords

DIGITONIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; DRUG UPTAKE; INTERNALIZATION; MEMBRANE BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELLS, CULTURED; DIGITONIN; KINETICS; MATHEMATICS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES; TIME FACTORS;

EID: 0032499403     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00649-7     Document Type: Article

References (37)

1. Ma DDF, Le Doan T. Antisense oligonucleotide therapies are they the "magic bullets"? Ann Intern Med Sci (Editorials). 120:1994;161-163.
2. Wagner RW. The state of the art in antisense research. Nature Med. 1:1995;1116-1118.
3. Sharma HW, Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays. 17:1995;1055-1063.
4. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Ann Rev Pharmacol Toxicol. 36:1996;107-129.
5. Putnam DA. Antisense strategies and therapeutic applications. Amer J Health-Syst Pharm. 53:1996;151-160.
6. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 86:1989;675-679.
7. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LA, Vlassov VV. Mechanism of oligonucleotide uptake by cells involvement of specific receptors? Proc Natl Acad Sci USA. 86:1989;6454-6458.
8. Yao JQ, Corrias S, Cheng YC. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. Biochem Pharmacol. 51:1996;431-436.
9. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDioniso L, Christensen L, Raible A, Jartt L, Gewirtz AM. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest. 95:1995;1814-1823.
10. Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2:1992;139-144.
11. Chin DJ, Green GA, Zon G, Szoka FC Jr, Straubinger RM. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biologist. 2:1990;1-9.
12. Wu-Pong S, Weiss TL, Hunt CA. Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res Dev. 4:1994;155-163.
13. Farrell CL, Bready JV, Kaufman SA, Qian YX, Burgess TL. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antisense Res Dev. 5:1995;175-183.
14. Leonetti JP, Mechti N, Degols G, Gagnor G, Lebleu B. Intracellular distribution of microinjected oligonucleotides. Proc Natl Acad Sci USA. 88:1991;2702-2706.
15. Lesh RE, Somlyo AP, Owens GK, Somlyo AV. Reversible permeabilization. A novel technique for the intracellular introduction of antisense oligonucleotides into intact smooth muscle. Circ Res. 77:1995;220-230.
16. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev. 5:1995;13-21.
17. Barry EL, Gesek FA, Friedman PA. Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O. Biotechniques. 15:1993;1016-1018.
18. Gao WY, Storm C, Egan W, Cheng YC. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Molec Pharmacol. 43:1993;45-50.
19. Cerruzzi M, Draper K, Schwartz J. Natural and phosphorothioate-modified oligodeoxyribonucleotides exhibit a non-random cellular distribution. Nucleos Nucleot. 9:1990;679-695.
20. Hughes JA, Avrutskaya AV, Juliano RL. Influence of base composition on membrane binding and cellular uptake of 10mer phosphorothioate oligonucleotides in chinese ovary (CHRC5) cells. Antisense Res Dev. 4:1994;211-215.
21. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood. 86:1995;3891-3896.
22. Delafontaine P, Meng X, Ku P, Du J. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides. J Biol Chem. 270:1995;14383-14388.
23. Nikol S, Huehns TY. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 123:1996;17-31.
24. Bauters C, Meurice T, Hamin M, McFadder E, Lablanche JM, Bertrand MT. Mechanisms and prevention of restenosis from experimental models to clinical practice . Cardiovasc Res. 31:1996;835-846.
25. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
26. Bennet MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 93:1994;820-828.
27. Zuurendonk PF, Tager JM. Rapid separation of particulate components and soluble cytoplasm of isolated rat liver cells. Biochim Biophys Acta. 333:1974;393-399.
28. Granger DL, Lehninger A. Sites of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol. 95:1982;527-535.
29. Diaz R, Wileman TE, Anderson SJ, Stahl P. The use of permeabilized cells to study the ion requirements of receptor-ligand dissociation in endosomes. Biochem J. 260:1989;127-134.
30. Legrand C, Bouc JM, Jacob C, Capiaumont J, Martial A, Marc A, Wudthe M, Kretzmer G, Demaugel C, Duval D, Hache J. Lactate Dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as a marker. J Biotechnol. 25:1992;231-243.
31. Vaes P, Jacques P. Subcellular localization of glycosidases in lysosomes. Neufeld EF, Ginsburg V. Methods in Enzymology. 1966;509-514 Academic Press, New York.
32. Lencer WI, Weyer P, Verkman AS, Ausiello DA, Brown D. FITC-Dextran as a probe for endosome function and localization in kidney. Am J Physiol. 258:1990;309-317.
33. Agrawal S, Tang JY. GEM-91 an antisense oligophosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev. 4:1992;261-266.
34. Wang WZ, Chen HJ, Schwartz A, Cannon PJ, Stein CA, Rabbani LE. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J Clin Invest. 98:1996;443-450.
35. Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides Antisense or anti-proteins? Antisense Res Dev. 5:1995;241.
36. Oldenburg KR, Vo KT, Smith GA, Selick HE. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J Pharmaceut Sci. 84:1995;915-921.
37. Temsamani J, Kubert M, Tang JY, Padmapriya A, Agrawal S. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev. 4:1994;35-42.